NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Kitov Pharmaceutical Holdings Ltd. (NASDAQ: KTOV) resulting from allegations that Kitov may have issued materially misleading business information to the investing public.
On February 6, 2017, the Israeli publication Calcalist reported that Kitov’s Chief Executive Officer, Isaac Israel, had been detained and questioned by the Israeli Securities Authority on suspicion of publishing misleading information in connection with a recent clinical trial of one of Kitov’s products. On this news, shares of Kitov fell $0.33 per share or over 11%, to close at $2.55 per share on February 6, 2017.
Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Kitov investors. If you purchased shares of Kitov before February 6, 2017 please visit the firm’s website at http://www.rosenlegal.com/cases-1051.html for more information. You may also contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at firstname.lastname@example.org or email@example.com.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.